ConductScience.org, home

Paper36005753

Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.

Peng Y and 2 others. Antimicrob Agents Chemother, 2022. Cited by 15 papers, by iCite.

Cite this record

ConductScience Library. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Papers, record 36005753. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36005753

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
2022
PubMed
Publication types
Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
15
iCite
Relative citation ratio, by iCite
1.76
iCite
Revised in PubMed
2023-02-26
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Peng YYaru
2Cheng ZZeneng
3Xie FFeifanhttps://orcid.org/0000-0002-9038-2676

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Continuous Renal Replacement TherapyMajor topic
Critical IllnessMajor topic
Adult
Anti-Bacterial Agents
Humans
Meropenem
Microbial Sensitivity Tests
Prospective Studies
Renal Replacement Therapy

Source PubMed

Download CSV of topics

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133818823
Population pharmacokinetics and probability of target attainment in patients with sepsis under renal replacement therapy receiving continuous infusion of meropenem: Sustained low-efficiency dialysis and continuous veno-venous haemodialysis.
Br J Clin Pharmacol2021https://conductscience.org/library/papers/33818823PubMed
226903338The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).JAMA2016https://conductscience.org/library/papers/26903338PubMed
330833427Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents.Antimicrob Agents Chemother2019https://conductscience.org/library/papers/30833427PubMed
433292582The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome.J Intensive Care2020https://conductscience.org/library/papers/33292582PubMed
525737147Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents.J Infect Chemother2015https://conductscience.org/library/papers/25737147PubMed
621914174Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.Crit Care2011https://conductscience.org/library/papers/21914174PubMed
710752806Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.Crit Care Med2000https://conductscience.org/library/papers/10752806PubMed
826124172Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.Antimicrob Agents Chemother2015https://conductscience.org/library/papers/26124172PubMed
99736573Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.Antimicrob Agents Chemother1998https://conductscience.org/library/papers/9736573PubMed
1014615469Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients.J Clin Pharmacol2003https://conductscience.org/library/papers/14615469PubMed
1116239363
Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients.
J Clin Pharmacol2005https://conductscience.org/library/papers/16239363PubMed
127648757Meropenem clinical pharmacokinetics.Clin Pharmacokinet1995https://conductscience.org/library/papers/7648757PubMed
1330376103
Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models.
J Antimicrob Chemother2019https://conductscience.org/library/papers/30376103PubMed
1411057794Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.Crit Care Med2000https://conductscience.org/library/papers/11057794PubMed
1512660337Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome.J Am Soc Nephrol2003https://conductscience.org/library/papers/12660337PubMed
1618307371Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.Clin Pharmacokinet2008https://conductscience.org/library/papers/18307371PubMed
1732543786Data Digitizing: Accurate and Precise Data Extraction for Quantitative Systems Pharmacology and Physiologically-Based Pharmacokinetic Modeling.CPT Pharmacometrics Syst Pharmacol2020https://conductscience.org/library/papers/32543786PubMed
1829091190Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships.J Antimicrob Chemother2017https://conductscience.org/library/papers/29091190PubMed
1925881576A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics.Crit Care2015https://conductscience.org/library/papers/25881576PubMed
2026598098Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics.Pharmacotherapy2015https://conductscience.org/library/papers/26598098PubMed

See all 37 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.

PMIDTitleJournalYearIn PapersSource
42950477Population pharmacokinetic model-based determination of enrofloxacin susceptibility breakpoints and dosing regimens for Salmonella in chickens.Poult Sci2026https://conductscience.org/library/papers/42950477PubMed
42882158Pharmacokinetic/Pharmacodynamic Optimization and Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Abdominal Sepsis: Current Evidence, Challenges, and Clinical Perspectives-A Narrative Review.J Clin Med2026https://conductscience.org/library/papers/42882158PubMed
42781062Prediction of Meropenem Target Attainment in Critically Ill Patients Using Routine Clinical Data from a Single Center: A Machine Learning Approach.Infect Drug Resist2026https://conductscience.org/library/papers/42781062PubMed
41792368Development and validation of a machine learning model for individualised meropenem dosing in CRRT patients.Sci Rep2026https://conductscience.org/library/papers/41792368PubMed
40955911Precision Dosing of Meropenem in a Neonate on CARPEDIEM Dialysis: A Grand Round.Ther Drug Monit2025https://conductscience.org/library/papers/40955911PubMed
40884551Population pharmacokinetics and pharmacodynamics of meropenem in critically ill patients with renal impairment or on continuous renal replacement therapy.Eur J Clin Pharmacol2025https://conductscience.org/library/papers/40884551PubMed
40421221Global research on the utilization of population pharmacokinetic model: a bibliometric analysis from 2000 to 2024.Front Pharmacol2025https://conductscience.org/library/papers/40421221PubMed
40265202Kidney replacement therapy during extracorporeal membrane oxygenation: pathophysiology, technical considerations, and outcomes.Ren Fail2025https://conductscience.org/library/papers/40265202PubMed
39991086
Population Pharmacokinetics of Prolonged Infusion for Meropenem: Tailoring Dosing Recommendations for Chinese Critically Ill Patients on Continuous Renal Replacement Therapy with Consideration for Renal Function.
Drug Des Devel Ther2025https://conductscience.org/library/papers/39991086PubMed
39200055Association between Extended Meropenem Regimen and Achievement of Aggressive PK/PD in Patients Receiving Continuous Renal Replacement Therapy for Septic AKI.Antibiotics (Basel)2024https://conductscience.org/library/papers/39200055PubMed
38656186How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children.Antimicrob Agents Chemother2024https://conductscience.org/library/papers/38656186PubMed
38410250Covariates in population pharmacokinetic studies of critically ill adults receiving β-lactam antimicrobials: a systematic review and narrative synthesis.JAC Antimicrob Resist2024https://conductscience.org/library/papers/38410250PubMed
37887225
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration.
Antibiotics (Basel)2023https://conductscience.org/library/papers/37887225PubMed
37366501Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients.Infect Drug Resist2023https://conductscience.org/library/papers/37366501PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36005753

GET https://conductscience.org/api/papers/v1/36005753/references?page=2